DALLAS, Jan. 10, 2005 (PRIMEZONE) -- TalkingStocks.com issued an update to our Profile Report on Biophan Technologies, Inc. (OTCBB:BIPH). The Profile Report is authored by Jeff Bishop, Senior Investment Analyst for TalkingStocks.com. The report outlines the strategic benefits to Biophan from the recently announced planned acquisition of AMRIS GmbH, a leading developer of new MRI technologies. Stents are a very large and lucrative market worldwide. Biophan is currently working in this area and has developed a thin-film nanomagnetic particle coating solution specifically for stents. The AMRIS solution uses a wire mesh wrapping which can bring this product to market much faster because it is added to existing stent designs. It does not require a costly redesign of the existing stent.
Biophan is undertaking a strategic decision of entering the EU by acquiring AMRIS, a leading developer of MRI safe technology and solutions. This acquisition will bring to Biophan not only additional patents held by the German company, but also very experienced and prominent personnel which will further help its business objectives.
This free report may be viewed in its entirety by visiting:
http://talkingstocks.com/reports/BIPH_011005.php
Registration is free.
About TalkingStocks.com
TalkingStocks.com offers interviews with key executives from publicly traded companies. TalkingStocks.com is owned by TalkingStocks.com, LLC. Our services include executive interviews, company profiles and investor calls.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 104 U.S. patents, licenses or applications. This total includes 25 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 70 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Disclosure: As of the date of this release, TalkingStocks.com, LLC, and its affiliate Pentony Enterprises, LLC (StockGuru.com), have been compensated an aggregate total of $18,000 for continuing coverage. The company paid $12,000 for coverage. Prior compensation of $6,000 came from Trilogy Capital Partners, the investor relations firm for Biophan Technologies (BIPH). Neither TalkingStocks.com, LLC, nor Pentony Enterprises, LLC, are registered investment advisers or broker/dealers. TalkingStocks.com, LLC and Pentony Enterprises, LLC makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.